Transcriptional response of MxA, PKR and SOCS3 to interferon-based therapy in HCV genotype 4-infected patients and contribution of p53 to host antiviral response

Intervirology

Volumn 55, Issue 3, 2012, Pages 210-218

  Hamdi, N ^a   El Akel, W ^b   El Serafy, M ^b   Esmat, G ^b   Sarrazin, C ^c   Abdelaziz, A I ^a  

^a German University in Cairo   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Double stranded RNA activated protein kinase; Genotype 4; Hepatitis C virus; Interferon ; Myxovirus resistance protein A; p53; Peripheral blood mononuclear cells; Suppressor of cytokine signaling 3

Indexed keywords

DOUBLE STRANDED RNA; MYXOVIRUS RESISTANCE PROTEIN A; PEGINTERFERON ALPHA2A; PROTEIN KINASE R; PROTEIN P53; RIBAVIRIN; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; GENE EXPRESSION; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

ADULT; ANTIVIRAL AGENTS; CELLS, CULTURED; EIF-2 KINASE; GENE EXPRESSION PROFILING; GENOTYPE; GTP-BINDING PROTEINS; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; MIDDLE AGED; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 4; ORTHOMYXOVIRIDAE;

EID: 84857912028     PISSN: 03005526     EISSN: 14230100     Source Type: Journal    
DOI: 10.1159/000327783     Document Type: Article

References (42)

1. WHO: World Health Organization. Hepatitis C. WHO Fact Sheet 164, 2000.
2. EMH: Egyptian Ministry of Health. Egyptian Ministry of Health Annual Report: 2007, Cairo 2007.
3. Nguyen MH, Keeffe EB: Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol 2005; 3:S97-S101. (Pubitemid 41427738)
4. Abdel-Aziz F, Habib M, Mohamed MK, Abdel-Hamid M, Gamil F, Madkour S, Mikhail NN, Thomas D, Fix AD, Strickland GT, Anwar W, Sallam I: Hepatitis C virus (HCV) infection in a community in the Nile delta: Population description and HCV prevalence. Hepatology 2000; 32: 111-115. (Pubitemid 30432374)
5. Strader DB, Wright T, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-1171. (Pubitemid 38428955)
6. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965. (Pubitemid 32913521)
7. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
8. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
9. Samuel CE: Antiviral actions of interferons. Clin Microbiol Rev 2001; 14: 778-809, table of contents. (Pubitemid 32979631)
10. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD: How cells respond to interferons. Annu Rev Biochem 1998; 67: 227-264. (Pubitemid 28411130)
11. Staeheli P, Pitossi F, Pavlovic J: Mx proteins: GTPases with antiviral activity. Trends Cell Biol 1993; 3: 268-272.
12. Arnheiter H, Frese M, Kambadur R, Meier E, Haller O: Mx transgenic mice-animal models of health. Curr Top Microbiol Immunol 1996; 206: 119-147.
13. Simon A, Fah J, Haller O, Staeheli P: Interferon-regulated Mx genes are not responsive to interleukin-1, tumor necrosis factor, and other cytokines. J Virol 1991; 65: 968-971.
14. Holzinger D, Jorns C, Stertz S, Boisson-Dupuis S, Thimme R, Weidmann M, Casanova JL, Haller O, Kochs G: Induction of MxA gene expression by influenza A virus requires type I or type III interferon signaling. J Virol 2007; 81: 7776-7785. (Pubitemid 47047864)
15. Gilli F, Marnetto F, Caldano M, Sala A, Malucchi S, Capobianco M, Bertolotto A: Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Mult Scler 2006; 12: 47-57. (Pubitemid 43169237)
16. Clemens MJ, Elia A: The double-stranded RNA-dependent protein kinase PKR: structure and function. J Interferon Cytokine Res 1997; 17: 503-524. (Pubitemid 27475916)
17. Samuel CE: Mechanism of interferon action: phosphorylation of protein synthesis initiation factor EIf-2 in interferon-treated human cells by a ribosome-associated kinase processing site specificity similar to hemin-regulated rabbit reticulocyte kinase. Proc Natl Acad Sci USA 1979; 76: 600-604. (Pubitemid 9135641)
18. Lee SB, Melkova Z, Yan W, Williams BR, Hovanessian AG, Esteban M: The interferon-induced double-stranded RNA-activated human p68 protein kinase potently inhibits protein synthesis in cultured cells. Virology 1993; 192: 380-385.
19. Kang JI, Kwon SN, Park SH, Kim YK, Choi SY, Kim JP, Ahn BY: PKR protein kinase is activated by hepatitis C virus and inhibits viral replication through translational control. Virus Res 2009; 142: 51-56.
20. Krebs DL, Hilton DJ: SOCS proteins: negative regulators of cytokine signaling. Stem Cells 2001; 19: 378-387. (Pubitemid 32900080)
21. Persico M, Capasso M, Persico E, Svelto M, Russo R, Spano D, Croce L, La Mura V, Moschella F, Masutti F, Torella R, Tiribelli C, Iolascon A: Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virusrelated chronic hepatitis: insulin resistance and response to antiviral therapy. Hepatology 2007; 46: 1009-1015. (Pubitemid 350144765)
22. Bode JG, Ludwig S, Ehrhardt C, Albrecht U, Erhardt A, Schaper F, Heinrich PC, Haussinger D: IFN- antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J 2003; 17: 488-490.
23. Persico M, Capasso M, Russo R, Persico E, Croce L, Tiribelli C, Iolascon A: Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C. Gut 2008; 57: 507-515. (Pubitemid 351442535)
24. Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, Powell EE: Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006; 55: 529-535.
25. Kim KA, Lin W, Tai AW, Shao RX, Weinberg E, De Sa Borges CB, Bhan AK, Zheng H, Kamegaya Y, Chung RT: Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection. J Hepatol 2009; 50: 705-711.
26. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, Sasaki S, Imai K, Shibue T, Honda K, Taniguchi T: Integration of interferon-/ signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003; 424: 516-523. (Pubitemid 36975769)
27. Dharel N, Kato N, Muroyama R, Taniguchi H, Otsuka M, Wang Y, Jazag A, Shao RX, Chang JH, Adler MK, Kawabe T, Omata M: Potential contribution of tumor suppressor p53 in the host defense against hepatitis C virus. Hepatology 2008; 47: 1136-1149. (Pubitemid 351547900)
28. Munoz-Fontela C, Macip S, Martinez-Sobrido L, Brown L, Ashour J, Garcia-Sastre A, Lee SW, Aaronson SA: Transcriptional role of p53 in interferon-mediated antiviral immunity. J Exp Med 2008; 205: 1929-1938.
29. Chen L, Borozan I, Feld J, Sun J, Tannis LL, Coltescu C, Heathcote J, Edwards AM, Mc-Gilvray ID: Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005; 128: 1437-1444. (Pubitemid 40712193)
30. Feld JJ, Nanda S, Huang Y, Chen W, Cam M, Pusek SN, Schweigler LM, Theodore D, Zacks SL, Liang TJ, Fried MW: Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology 2007; 46: 1548-1563. (Pubitemid 350155537)
31. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W, Heim MH: Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 2008; 105: 7034-7039. (Pubitemid 351754525)
32. Gerotto M, Dal Pero F, Bortoletto G, Realdon S, Ferrari A, Boccato S, Alberti A: Pkr gene expression and response to pegylated interferon plus ribavirin therapy in chronic hepatitis C. Antivir Ther 2004; 9: 763-770. (Pubitemid 39434340)
33. MacQuillan GC, Mamotte C, Reed WD, Jeffrey GP, Allan JE: Upregulation of endogenous intrahepatic interferon stimulated genes during chronic hepatitis C virus infection. J Med Virol 2003; 70: 219-227. (Pubitemid 36520630)
34. Pham TN, Macparland SA, Coffin CS, Lee SS, Bursey FR, Michalak TI: Mitogen-induced upregulation of hepatitis C virus expression in human lymphoid cells. J Gen Virol 2005; 86: 657-666. (Pubitemid 40331246)
35. Chieux V, Hober D, Harvey J, Lion G, Lucidarme D, Forzy G, Duhamel M, Cousin J, Ducoulombier H, Wattre P: The MxA protein levels in whole blood lysates of patients with various viral infections. J Virol Methods 1998; 70: 183-191. (Pubitemid 28132821)
36. Roers A, Hochkeppel HK, Horisberger MA, Hovanessian A, Haller O: MxA gene expression after live virus vaccination: a sensitive marker for endogenous type I interferon. J Infect Dis 1994; 169: 807-813. (Pubitemid 24102114)
37. de Lucas S, Bartolome J, Carreno V: Hepatitis C virus core protein down-regulates transcription of interferon-induced antiviral genes. J Infect Dis 2005; 191: 93-99. (Pubitemid 40041406)
38. Colonna M, Krug A, Cella M: Interferonproducing cells: on the front line in immune responses against pathogens. Curr Opin Immunol 2002; 14: 373-379. (Pubitemid 34327981)
39. Mihm S, Frese M, Meier V, Wietzke-Braun P, Scharf JG, Bartenschlager R, Ramadori G: Interferon type I gene expression in chronic hepatitis C. Lab Invest 2004; 84: 1148-1159. (Pubitemid 39128260)
40. He XS, Ji X, Hale MB, Cheung R, Ahmed A, Guo Y, Nolan GP, Pfeffer LM, Wright TL, Risch N, Tibshirani R, Greenberg HB: Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. Hepatology 2006; 44: 352-359. (Pubitemid 44214874)
41. Taylor MW, Tsukahara T, Brodsky L, Schaley J, Sanda C, Stephens MJ, McClintick JN, Edenberg HJ, Li L, Tavis JE, Howell C, Belle SH: Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J Virol 2007; 81: 3391-3401. (Pubitemid 46456648)
42. Huang Y, Feld JJ, Sapp RK, Nanda S, Lin JH, Blatt LM, Fried MW, Murthy K, Liang TJ: Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. Gastroenterology 2007; 132: 733-744. (Pubitemid 46274665)